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Introduction
Maroteaux-Lamy syndrome, or mucopolysaccharidosis type VI (MPS VI), is an autosomal recessive inborn error of lysosomal metabolism resulting from the deficient activity of arylsulfatase B (ASB; N-acetylgalactosamine-4-sulfatase; E.C. 3.1.6.1). 1 The resultant accumulation of the glycosaminoglycan, dermatan sulfate, is clinically manifested in MPS VI patients by severe bone and connective tissue deformities, facial dysmorphia, cardiopulmonary complications, hepatosplenomegaly and corneal clouding. 1 MPS VI has also been described in cats, rats and dogs. [2] [3] [4] Bone marrow transplantation (BMT), enzyme replacement and hematopoietic stem cell gene therapy (HSCGT) have been considered and/or evaluated in human MPS VI patients and in animal models. [5] [6] [7] [8] [9] [10] [11] Clinically, BMT in human patients has not been successful in correcting the skeletal pathology or corneal clouding, although biochemical and pathological improvements have been noted in several other relevant organs, such as the heart and trachea. 5, 6 In MPS VI cats, BMT has led to modest improvements in locomotor skills and some reduction of long bone disfigurement, although wide-spread correction of the skeletal phenotype was not achieved, nor was a reduction in the corneal clouding. [8] [9] [10] Similar findings have been obtained in MPS VI rats.
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From these studies it may be concluded that BMT has modest effects on the skeletal system in MPS VI, but can result in significant improvements in other clinically relevant organs. Unfortunately, since most MPS VI families are small, allogeneic BMT is not a viable option because of the lack of histocompatible donor cells. On the other hand, HSCGT using gene-modified, autologous cells, is a reasonable alternative to allogeneic BMT for the treat-ment of this disease (for a recent review, see Ref. 12) . As compared with allogeneic BMT, HSCGT offers the advantages of reduced graft-versus-host disease, resulting in decreased morbidity and mortality, and no limitation on the availability of histocompatible donor cells. Moreover, genetic manipulation of the transplanted cells could also lead to greater than normal levels of enzymatic expression and/or secretion of the therapeutic proteins.
While HSCGT has been successfully achieved in mice (for example, see , in larger animals the situation has not been straight forward. This may reflect differences in stem cell biology, as well as difficulties in managing the morbity associated with myeloablation using lethal doses of total body irradiation (TBI). Indeed, due to these complications, far fewer studies of this nature have been carried out in large animal species, and the data in animals other than mice are incomplete.
The experiments described in this paper were undertaken to evaluate whether retroviral transduction of longterm repopulating cat hematopoietic cells could be achieved, and to evaluate specifically a long-term bone marrow culture/transduction protocol that had been originally developed in dogs and shown to be effective in the absence of myeloablation. 17, 18 In addition, we had the unique advantage of having a feline model of a human genetic disease (ie MPS VI cats), permitting the assessment of clinical efficacy. As an alternative to HSCGT using bone marrow cells, we also transplanted two cats with retrovirally transduced peripheral blood cells collected from MPS VI kittens within 24 h of birth. Such neonatal cells are similar to human cord blood cells, 19 and are an additional source of hematopoietic stem cells that has attracted significant interest.
Results
Eight MPS VI cats were autologously transplanted with retrovirally transduced BM or neonatal blood cells (Table  1) , and ASB activities were monitored for up to 31 months after transplantation in mixed white blood cell populations (WBCs), fractionated granulocytes or lymphocytes, and/or bone marrow (BM) cells (Figure 1a) . The transducing MFG retroviral vector (see Materials and methods for details on the construction of this vector, as 4 , which had evidence of enzymatic activity in its bone marrow cells for 6 months and lymphocytes for 8 months, never had ASB activity in its granulocytes. Moreover, in cat No. 2, which was positive for ASB activity in BM cells taken from the right femur at 28 months after transplantation, samples aspirated from the humeri and left femur at the same time-point were negative (not shown).
Among the two animals transplanted with neonatal blood cells, cat No. 7 was enzyme positive in BM cells and WBCs (not shown) for 13 months after transplant (but not in granulocytes), while cat No. 8 only had ASB activity in WBCs (for 13 months after transplant; not shown). Of particular note, despite clear evidence of enzyme expression in many individual cell populations from several different animals, the highest level of enzyme activity observed in any sample was only approximately 20% of normal. It should be noted that before transplantation, the bulk BM cultures were assayed for ASB activity and found to have activities that were in the normal (or above normal) range (not shown). These results are in agreement with those previously published. 20 The ASB/MFG vector also has been previously shown to transduce between 30 and 50% of the CFU-GM-derived colonies from MPS VI BM. 20 A PCR/Southern blotting assay was developed for the detection of the MFG-hASB provirus and used to analyze WBCs, granulocytes, lymphocytes and/or BM cells of the transplanted animals ( Figure 1b ). Cell populations that gave a positive signal after Southern blotting were considered 'vector positive', and based on cell mixing experiments (see Materials and methods for details), were estimated to contain at least 0.05% transduced cells. In the animals transplanted with transduced BM cells, the presence of vector-positive cells was detected up to 24 months in the granulocytes and lymphocytes, and 31 months in BM cells. Again, as was the case with the enzyme results, not all animals were vector positive in all samples at any given time-point. In all of the samples obtained from the transplanted cats, with the exception of the BM cells from cat No. 6 at 12 months after transplantation, proviral DNA was detected for longer periods of time than ASB activity (see Figure 1 ). The positive enzymatic activity in the BM cells from cat No. 6 may be derived from ASB that was secreted from transduced blood cells and taken up by the BM cells, since WBCs and granulocytes were positive for ASB activity at this time-point. Previous work has documented the fact that BM cells transduced with the ASB/MFG vector can release ASB that can be readily taken up by cultured cells. 20 In addition, in some samples (eg cat No. 5 BM cells and cat No. 7 Table 1 ).
Figure 1 Detection of ASB activity and the MFG-hASB provirus in BM cells, granulocytes and lymphocytes of MPS VI cats transplanted with retrovirally transduced BM (cats Nos 1-6) and neonatal blood (cats Nos 7 and 8) cells. (a) ASB activities in the various cell populations. (b) PCR/Southern blotting analysis of the ASB/MFG vector in various cell
granulocytes) there was exclusive detection of the provirus without any ASB activity. While we attempted to carry out both PCR and enzymatic assays on all samples obtained throughout the duration of this experiment, after the cell fractionation procedure the yield of individual cell types was occasionally too small to permit both analyses to be carried out. In these cases, we chose to perform the PCR analysis since this assay was more sensitive and required less cells.
In the animals transplanted with transduced neonatal blood cells, the presence of proviral DNA was detected for up to 12 months after transplant in the WBCs (not shown), 10 months in the granulocytes, and 6 months in the lymphocytes. Of particular interest, in one of these animals (cat No. 7) the BM cells were clearly vector positive in both humeri and femurs for 13 months (the duration of the experiment; Figure 2 ). In another cat transplanted with transduced BM cells (cat No. 1), vector- a ASB activities were carried out using p-nitrocatecol sulfate as a substrate. 27 The numbers indicate the nmol of substrate cleaved/min/mg of cellular protein, and were derived from analysis of at least five different normal and MPS VI animals. positive cells were found in several independent bone sites 31 months after transplant (Figure 2) . Neither of these animals received myeloablative preconditioning before transplantation.
Figure 2 Detection of the MFG-hASB provirus in BM cells
Clinically, the transplanted animals showed no improvement in their locomotor skills, resolution of corneal clouding or facial dysmorphology. Radiographic studies of the transplanted animals confirmed these observations (not shown). To determine whether the lack of clinical improvement was due to an immune response against the vector encoded human enzyme, ELISA assays were performed. Antibody titers were evaluated in normal control, untreated MPS VI cats and the transplanted MPS VI cats, but no evidence of increased anti-hASB antibodies was found in the transplanted animals compared with the controls (Figure 3 ). The reliability of this ASBspecific ELISA method has been previously documented in MPS VI cats infused with recombinant hASB.
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Discussion
The current study was initially undertaken to evaluate in cats an earlier report in dogs suggesting that the longterm persistence of retrovirally transduced BM cells could be achieved in the absence of myeloablation. 18 Our experimental design was based, in part, on this earlier report, and involved repeated exposure of BM cells to fresh virus-containing media over a 2-week period. Important aspects of our study included: (1) demonstration of long-term (Ͼ2.5 years), in vivo gene transfer in cats; and (2) the use of a large animal model for a human genetic disease (MPS VI), and transduction with a potentially therapeutic gene (ASB). In addition, in vivo experiments using retrovirally transduced neonatal blood cells were evaluated, as were the effects of various myeloablation protocols and recipient age.
The results described within clearly documented the fact that the long-term persistence of retrovirally transduced cells could be achieved in autologously transplanted cats, even in the absence of myeloablation. The only growth factor added to the BM cultures during the 2-week transduction procedure was recombinant canine stem cell factor (rc-SCF), suggesting that culture in the presence of this growth factor allowed some of the cat hematopoietic stem cells to undergo cell division, thus making them transduction competent. It must also be
Figure 3 Anti-hASB antibody titers in untransplanted and transplanted MPS VI cats. Cats Nos 1-6 were transplanted with BM cells, and cats Nos 7 and 8 were transplanted with neonatal blood cells as described in the text. Assays were performed from 12 to 28 months after transplantation. A previous study 21 demonstrated anti-hASB plasma titers of 8390 ± 7277 for untreated MPS VI control cats and 10 343 ± 13 846 for normal control cats. The highest recorded antibody titers in both of these control groups was 40 000.
noted that stromal cell layers formed in these cultures during the 2-week growth period, and that the stromal cells themselves may have provided valuable growth factors which contributed to these results.
We believe that our findings demonstrate the transduction of cat hematopoietic stem (or very early progenitor) cells because: (1) the PCR/Southern blotting assay showed that several different cell-specific lineages (eg lymphocytes and granulocytes) were vector positive; (2) many of these cell populations were vector positive for more than 2 years after transplant; and (3) such differentiated hematopoietic cells are stem, not stromal, cell derived.
Of note, similar results were obtained in myeloablated animals which received sublethal levels of TBI as compared with animals which were not irradiated, confirming the earlier results obtained in dogs demonstrating engraftment of transduced cells in the absence of myeloablation. 18 In fact, the transplanted cat which demonstrated the longest persistence of transduced cells (31 months; cat No. 1) received no myeloablation. Data concerning whether myeloablation is necessary for successful engraftment and the long-term persistence of autologously transplanted cells are conflicting. While some investigators suggest that myeloablation is necessary for the engraftment of transplanted cells (for example, Ref. 22) , our results and those of others (for example, Ref. 18) suggest that this may not always be the case. Since myeloablative procedures can lead to high morbidity in treated patients, this aspect of HSCGT must be thoroughly investigated in large animal systems before such procedures are used in humans.
We also transplanted two young MPS VI kittens with retrovirally transduced neonatal blood cells collected immediately after birth. Such neonatal blood cells resemble cord blood cells, 19 and are of interest for transplantation and gene therapy since there is evidence suggesting that: (1) engraftment of such cells can be achieved in HLA-disparent donors and recipients; 23 and (2) retroviral transduction of hematopoietic neonatal blood stem cells may be easier to achieve than transduction of stem cells from the bone marrow. 19, 24 In both of our transplanted animals, evidence for transduction of long-term repopulating cells was obtained, even in the absence of myeloablation.
To our knowledge, these are some of the first in vivo experiments carried out using retrovirally transduced neonatal (or cord) blood cells. One previous report has appeared in which adenosine deaminase (ADA)-deficient infants with severe combined immune deficiency were transplanted with neonatal blood which had been transduced with a retroviral vector encoding wild-type ADA. 25 However, since it is well documented that ADAexpressing T cells have a competitive growth/survival advantage over non-ADA-expressing cells after transplantation into ADA-deficient recipients, 26 we believed that it was important to confirm these findings using a gene for which no such competitive advantage has been described (ie ASB).
Despite the positive results described above, the levels of ASB activity in these cells was disappointingly low. Concurrently, no clinical effect of the gene therapy procedure was noted. These results were not due to an immune response against the human enzyme encoded by the MFG vector, and may be explained by a low stem cell transduction efficiency and/or vector shut-down. Of note, while all of the animals remained vector positive for many months after transplantation, the sensitivity of the PCR assay was such that as few as 1:1000 vectorpositive cells could be present in any of the 'PCR positive' samples.
Based on these findings, the lack of clinical improvement in the engrafted animals was not unexpected. In fact, BMT studies in MPS VI rats have already shown that even when complete engraftment and normal levels of ASB activity were achieved by 3 weeks of age and persisted for many months after transplant, the clinical effects on the skeletal system were minimal. 8 Similar results have been reported in MPS VI cats undergoing enzyme replacement therapy, suggesting that proliferating chondrocytes, the primary cellular site of pathology in this and other MPS diseases, are not amenable to enzymatic cross-correction in vivo. Since we have previously shown using an in vitro system that retrovirally transduced hematopoietic cells release ASB that is readily taken up by fibroblasts and chondrocytes via the mannose-6-phospahte receptor system, the lack of success in the clinical setting probably reflects the inability of soluble enzymes released into the circulation to reach these important cells. Thus, to treat the skeletal disease in MPS VI efficiently, more efficient targeting to chondrocytes in vivo must be achieved, along with increased secretion of the targeted enzyme from the engrafted cells.
In conclusion, we believe that the most significant result obtained from these studies was that long-term engraftment of retrovirally transduced hematopoietic stem cells could be achieved in cats without any myeloablative preconditioning. This was observed using either transduced bone marrow or neonatal blood cells.
Futher studies of this type are necessary in large animal systems to develop future HSCGT protocols for human patients.
Materials and methods
Retroviral vector
The ASB/MFG retroviral vector was constructed by inserting the full-length hASB cDNA into the MFG vector as previously described. 20 Briefly, PCR mutagenesis was used to introduce an NcoI restriction site into the translation inititation codon of the wild-type ASB sequence in order to optimize translation and facilitate cloning. To generate packaging cell lines producing the ASB/MFG vector, envAM12 amphotropic packaging cells were coelectroporated with the ASB/MFG vector and the pSV2Neo plasmid at a molar ratio of 20:1. Following G418 selection (0.4 mg/ml), medium was collected from 14 resistant colonies, serial dilutions were prepared and used to transduce NIH 3T3 cells. Following transduction, ASB activity was determined in the cells using pnitrocatecol sulfate. 27 A 'high titer' clone (AMFG-1) was selected based on its ability to produce high levels of ASB activity in the transduced NIH 3T3 cells. 20 Similar methods of estimating titer based on enzymatic activity have been published for MFG vectors encoding several other therapeutic proteins for which no selection system exists (for example, see Ref. 28 ).
Retroviral transduction and autologous transplantation
MPS VI cats were maintained at the University of Pennsylvania School of Veterinary Medicine under NIH and USDA guidelines for the care and use of animals for research. The animals were housed at 21°C with ad libitum food and water, 12 h light cycles, and 12-15 air changes per hour. Affected MPS VI kittens were diagnosed by determining ASB activity in WBCs. 24 Eight MPS VI cats ranging in age from 2 weeks to 12 months received autologous transplants using retrovirally transduced BM or neonatal blood cells. For bone marrow collection, induction and intubation was performed using ketamine hydrochloride, and anesthesia was maintained with fluotane. Bone marrow was aspirated from both humeri, femurs, tibias and/or iliac crests into preservative-free heparin and shipped overnight from the University of Pennsylvania to Mount Sinai at room temperature. Bone marrow cultures (LTMC) were transduced with the human ASB/MFG in the presence of rc-SCF as previously described by Fillat et al. 20 At the end of the 2-week culture/transduction period, the BM cells were assayed for enzymatic activity to ensure transduction before they were shipped back to the University of Pennsylvania for subsequent transplantation into the MPS VI cats. Between 5.6 × 10 5 and 1.5 × 10 8 retrovirally transduced cells/kg of body weight were re-infused intravenously (i.v.) into each cat. Two cats received 377-390 cGy, and one received 190 cGy from a linear accelerator 18 h before infusion of vector-treated cells. Three cats received no conditioning.
Neonatal blood cells were collected from two 24-h-old MPS VI kittens, placed into culture, and transduced in the presence of rc-SCF as described above. The viral supernatants were concentrated approximately 20-fold in Macrosep (Filtron Technology Corporation, Northborough, MA, USA) centrifugal ultrafilters with a molecular cut-off of 300 kDa before being added to the culture medium. Following transduction, the unconditioned 2-week-old kittens were infused i.v. with 2.2 × 10 7 and 5.9 × 10 7 retrovirally transduced cells/kg of body weight. Animals transplanted with BM were maintained for between 12 and 31 months after BMT, while neonatal blood recipients were maintained for 13 months after transplant. All cats were killed using concentrated sodium pentobarbital in accordance with the American Veterinary Medical Association guidelines.
ASB and protein assays
WBCs, granulocytes, lymphocytes and BM (taken from various sites) were collected at regular intervals for ASB assays. At the termination of the experiment, BM was aspirated from both humeri and femurs. ASB activities were assayed using p-nitrocatecol sulfate as a substrate. 27 Protein determinations were performed using a protein assay kit according to the manufacturer's instructions (BioRad, Richmond, CA, USA).
Detection of the MFG provirus by PCR and Southern blotting analysis Genomic DNA was isolated from WBCs, granulocytes, lymphocytes and BM cells at regular intervals using Puregene kits (Gentra Systems, Minneapolis, MN, USA). The following oligonucleotides specific for the human ASB cDNA were used to generate a 559-bp product: sense primer: 5Ј-GGTCGGAAAATGGCACCTGGGAA-3Ј, antisense primer: 5Ј-CCCTCGGACGCCTCCTTCCCACA-3Ј. PCR amplification was carried out in a 50 l reaction mixture containing 100 pmol of each PCR primer. After an initial denaturation for 10 min, 1.0 U of Taq polymerase was added. The reactions were subjected to 35 cycles of denaturation at 94°C for 1 min, annealing at 68°C for 1 min, extension at 72°C for 2 min, and DNA polymerization at 72°C for 15 min. Negative controls contained template DNA prepared from cells which had not been transduced.
To ensure detection of the vector-derived hASB sequence (and not the endogenous cat ASB gene or other sulfatases), Southern blotting was performed using a probe specific for the hASB sequence. After the PCR, the entire reaction was analyzed by gel electrophoresis on a 1% agarose gel and visualized by ethidium-bromide staining. The products were then transferred to ZetaProbe blotting membrane (Bio-Rad) for Southern hybridization analysis. An 18-mer (5Ј-CACCAA AAGGGCTAT-3Ј) specific for human ASB was designed as a probe. The sequence was end-labeled with ␥-32 P ATP using T4 polynucleotide kinase. Following hybridization at 50°C for at least 12 h, the blots were washed for 5 min in 2 × SSC containing 0.5% SDS at room temperature, followed by a 15 min wash in 2 × SSC containing 0.1% SDS.
To test the reliability and sensitivity of this reaction, cell mixing experiments were carried out. Cultures of the ASB/MFG producer cell line and cat BM cells were harvested and counted using a hemocytometer. Previous experiments had shown that the producer cells contained approximately one copy of the ASB/MFG vector per cell. 20 Different dilutions of the two cell populations were made such that the frequency of the producer cells ranged from 0.0001 to 1%; genomic DNA was then pre-pared and the PCR/Southern blotting assay was carried out. The results of these studies revealed that a PCR product could be reliably detected by Southern blotting when the frequency of transduced cells in the mixture was 0.1% or greater, but not when the the frequency was 0.05% or lower.
Immunoassay of anti-human ASB antibodies An ELISA assay was used to determine the titer of antihuman ASB antibodies in the plasma of the transplanted animals as previously described. 21 Antibody titers were calculated as the least positive dilution which was greater than 2 standard deviations either side of background for the assay.
